205
Participants
Start Date
July 1, 2019
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2022
Len+DEB-TACE+HAIC
Patients received TACE with drug-eluting beads and FOLFOX-HAIC. DEB-TACE and/or HAIC was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight \<60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.
Len+DEB-TACE
Patients received TACE with drug-eluting beads. DEB-TACE was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight \<60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou
Zhongshan People's Hospital, Guangdong, China
OTHER
Affiliate Hospital of Guangdong Medical University
UNKNOWN
Jieyang People's Hospital
OTHER
Huizhou Municipal Central Hospital
OTHER
Guangzhou Development District Hospital
UNKNOWN
Affiliated Hospital of Nanjing University of Chinese Medicine
OTHER
First People's Hospital of Foshan
OTHER
Second Affiliated Hospital of Guangzhou Medical University
OTHER